The FDA accepts for review Chiasma’s (CHMA +1.3%) resubmitted marketing application for Mycapssa (octreotide) for the maintenance treatment of adults with acromegaly.
The agency’s action date is June 26.
The company received a CRL in April 2016 citing the need for an additional clinical trial.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.